- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
Novo Nordisk submitted a new dose for its obesity drug, driven by intensifying competition in the weight loss market.
1 report, 0 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk submitted a new dose for its obesity drug, driven by intensifying competition in the weight loss market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.Also in this story
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Mounjaro's approval caused a decline in Trulicity sales, marking a specific development in the weight loss drug market.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
Related events
Coverage
Newest first; wire copies grouped- Unknown outlet